|
gptkbp:instanceOf
|
gptkb:chemical_compound
|
|
gptkbp:approvalYear
|
2003
|
|
gptkbp:approvedBy
|
gptkb:FDA
|
|
gptkbp:ATCCode
|
L01XX32
|
|
gptkbp:CASNumber
|
gptkb:168273-06-1
|
|
gptkbp:discoveredBy
|
gptkb:Julian_Adams
|
|
gptkbp:drugClass
|
gptkb:protease_inhibitor
|
|
gptkbp:hasInChIKey
|
WTDRJLZQGIEQPN-VXGBXAGGSA-N
|
|
gptkbp:hasMolecularFormula
|
C19H25BN4O4
|
|
gptkbp:hasSMILES
|
CC(C)C[C@@H](NC(=O)[C@@H](NC(=O)c1ccccc1)B(O)O)C(=O)N
|
|
gptkbp:hasUNII
|
QPL8W5566P
|
|
gptkbp:marketedAs
|
gptkb:Takeda_Pharmaceutical_Company
gptkb:Millennium_Pharmaceuticals
|
|
gptkbp:mechanismOfAction
|
inhibits 26S proteasome
|
|
gptkbp:molecularWeight
|
384.24 g/mol
|
|
gptkbp:name
|
gptkb:Bortezomib
|
|
gptkbp:patentExpired
|
yes
|
|
gptkbp:pregnancyCategory
|
D (US)
|
|
gptkbp:PubChem_CID
|
387447
CHEMBL325041
DB00188
|
|
gptkbp:routeOfAdministration
|
subcutaneous
intravenous
|
|
gptkbp:sideEffect
|
gptkb:peripheral_neuropathy
thrombocytopenia
gastrointestinal symptoms
|
|
gptkbp:synonym
|
gptkb:MLN341
gptkb:PS-341
gptkb:Velcade
|
|
gptkbp:usedForTreatmentOf
|
gptkb:mantle_cell_lymphoma
multiple myeloma
|
|
gptkbp:bfsParent
|
gptkb:SR141716A
gptkb:rimonabant
|
|
gptkbp:bfsLayer
|
7
|
|
http://www.w3.org/2000/01/rdf-schema#label
|
168273-06-1
|